Literature DB >> 18593984

Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.

Daphne W Bell1, Brian W Brannigan, Keitaro Matsuo, Dianne M Finkelstein, Raffaella Sordella, Jeff Settleman, Tetsuya Mitsudomi, Daniel A Haber.   

Abstract

PURPOSE: Somatic mutations in the epidermal growth factor receptor (EGFR) gene occur in a subset of non-small-cell lung cancer (NSCLC) and are highly predictive of the clinical response to selective EGFR kinase inhibitors. The prevalence of EGFR-mutant NSCLC is appreciably higher in females than in males and in East Asian than in Caucasian populations. We hypothesized that these disparate frequencies may be attributable to underlying genetic modifiers. Given the coincident differences in sex and ethnic origin, we tested allozymatic variants of enzymes involved in estrogen biosynthesis and metabolism, encoded by polymorphic alleles known to differ in frequency between Caucasian and Asian populations, as modifying alleles. EXPERIMENTAL
DESIGN: We genotyped nine polymorphisms in the CYP1A1, CYP17A1, CYP19, HSD17B1, COMT, GSTM1, and GSTT1 genes, in a series of 100 Japanese NSCLCs, selected for equal representation of EGFR wild-type (wt) and EGFR-mutant cases, as well as male and female cases. Associations between polymorphic variants and the EGFR genotype and sex of NSCLC cases were examined using Fisher's exact test of significance.
RESULTS: Only CYP1A1 2C showed a difference in allele frequency that approached statistical significance. Heterozygotes were underrepresented among EGFR-mutant cases compared with EGFR-wt cases (27% versus 47%, P = 0.08), with a concurrent trend toward overrepresentation of CYP1A1 2C(Ile/Ile) homozygotes among EGFR-mutant cases as compared with EGFR-wt cases (69% versus 51%, P = 0.13).
CONCLUSION: Within the power of this study, our findings suggest that the selected polymorphic variants in the estrogen biosynthesis and metabolism pathways are unlikely to be major genetic modifiers of the prevalence of EGFR-mutant NSCLC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593984      PMCID: PMC3391698          DOI: 10.1158/1078-0432.CCR-07-5030

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

Review 1.  Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women.

Authors:  Yasuo Miyoshi; Shinzaburo Noguchi
Journal:  Biomed Pharmacother       Date:  2003-12       Impact factor: 6.529

2.  Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women.

Authors:  Montserrat García-Closas; Julie Herbstman; Mark Schiffman; Andrew Glass; Joanne F Dorgan
Journal:  Int J Cancer       Date:  2002-11-10       Impact factor: 7.396

3.  Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.

Authors:  Timo Salmen; Anna-Mari Heikkinen; Anitta Mahonen; Heikki Kröger; Marja Komulainen; Heli Pallonen; Seppo Saarikoski; Risto Honkanen; Pekka H Mäenpää
Journal:  Ann Med       Date:  2003       Impact factor: 4.709

4.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

5.  HSD17B1 gene polymorphisms and risk of endometrial and breast cancer.

Authors:  Veronica Wendy Setiawan; Susan E Hankinson; Graham A Colditz; David J Hunter; Immaculata De Vivo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-02       Impact factor: 4.254

6.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

7.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.

Authors:  Raffaella Sordella; Daphne W Bell; Daniel A Haber; Jeffrey Settleman
Journal:  Science       Date:  2004-07-29       Impact factor: 47.728

9.  Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women.

Authors:  Shelley S Tworoger; Jessica Chubak; Erin J Aiello; Cornelia M Ulrich; Charlotte Atkinson; John D Potter; Yutaka Yasui; Patricia L Stapleton; Johanna W Lampe; Federico M Farin; Frank Z Stanczyk; Anne McTiernan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-01       Impact factor: 4.254

10.  Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women.

Authors:  Meng Hua Tao; Qiuyin Cai; Zuo-Feng Zhang; Wang-Hong Xu; Nobuhiko Kataoka; Wanqing Wen; Yong-Bing Xiang; Wei Zheng; Xiao Ou Shu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-05       Impact factor: 4.254

View more
  25 in total

1.  Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.

Authors:  Vei Mah; Diana Marquez; Mohammad Alavi; Erin L Maresh; Li Zhang; Nam Yoon; Steve Horvath; Lora Bagryanova; Michael C Fishbein; David Chia; Richard Pietras; Lee Goodglick
Journal:  Lung Cancer       Date:  2011-04-20       Impact factor: 5.705

2.  Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients.

Authors:  Yen-Hsiang Huang; Kuo-Hsuan Hsu; Jeng-Sen Tseng; Kun-Chieh Chen; Kang-Yi Su; Hsuan-Yu Chen; Chi-Sheng Chang; Jeremy J W Chen; Sung-Liang Yu; Huei-Wen Chen; Tsung-Ying Yang; Gee-Chen Chang
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.

Authors:  Qiao-Yang Sun; Ling-Wen Ding; Jin-Fen Xiao; Wenwen Chien; Su-Lin Lim; Norimichi Hattori; Lee Goodglick; David Chia; Vei Mah; Mohammad Alavi; Sara R Kim; Ngan B Doan; Jonathan W Said; Xin-Yi Loh; Liang Xu; Li-Zhen Liu; Henry Yang; Takahide Hayano; Shuo Shi; Dong Xie; De-Chen Lin; H Phillip Koeffler
Journal:  J Pathol       Date:  2014-12-18       Impact factor: 7.996

4.  Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer.

Authors:  Kyung Rae Cho; Min Ho Lee; Doo-Sik Kong; Ho Jun Seol; Do-Hyun Nam; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park; Sung Tae Kim; Do Hun Lim; Jung-Il Lee
Journal:  J Neurooncol       Date:  2015-09-15       Impact factor: 4.130

5.  Identifying candidates for gamma knife radiosurgery among elderly patients with brain metastases.

Authors:  Tae Hoon Roh; Mi Sun Choi; Namkyu You; Donghwan Jeong; Ae Hwa Jang; Mi Ra Seo; Sang Ryul Lee; Se-Hyuk Kim
Journal:  J Neurooncol       Date:  2018-01-11       Impact factor: 4.130

6.  The role of molecular pathology in non-small-cell lung carcinoma-now and in the future.

Authors:  G D A Brandao; E F Brega; A Spatz
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

7.  Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma.

Authors:  Soley Bayraktar; Caio M Rocha-Lima
Journal:  World J Clin Oncol       Date:  2013-05-10

Review 8.  A practical and adaptive approach to lung cancer screening: a review of international evidence and position on CT lung cancer screening in the Singaporean population by the College of Radiologists Singapore.

Authors:  Charlene Jin Yee Liew; Lester Chee Hao Leong; Lynette Li San Teo; Ching Ching Ong; Foong Koon Cheah; Wei Ping Tham; Haja Mohamed Mohideen Salahudeen; Chau Hung Lee; Gregory Jon Leng Kaw; Augustine Kim Huat Tee; Ian Yu Yan Tsou; Kiang Hiong Tay; Raymond Quah; Bien Peng Tan; Hong Chou; Daniel Tan; Angeline Choo Choo Poh; Andrew Gee Seng Tan
Journal:  Singapore Med J       Date:  2019-11       Impact factor: 1.858

9.  Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.

Authors:  Hailiang Zhang; Baijun Dong; Jiade J Lu; Xudong Yao; Shilin Zhang; Bo Dai; Yijun Shen; Yao Zhu; Dingwei Ye; Yiran Huang
Journal:  BMC Cancer       Date:  2009-07-21       Impact factor: 4.430

10.  A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.

Authors:  Sheila E Taube; Gary M Clark; Janet E Dancey; Lisa M McShane; Caroline C Sigman; Steven I Gutman
Journal:  J Natl Cancer Inst       Date:  2009-10-23       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.